Last reviewed · How we verify
HDM SLIT-tablet
HDM SLIT-tablet is a sublingual immunotherapy that delivers house dust mite allergen extract to induce immune tolerance and reduce allergic responses.
HDM SLIT-tablet is a sublingual immunotherapy that delivers house dust mite allergen extract to induce immune tolerance and reduce allergic responses. Used for Allergic rhinitis and/or allergic asthma induced by house dust mite allergen.
At a glance
| Generic name | HDM SLIT-tablet |
|---|---|
| Also known as | Acarizax, Odactra, ACARIZAX, ODACTRA |
| Sponsor | ALK-Abelló A/S |
| Drug class | Sublingual immunotherapy (SLIT) tablet |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This sublingual immunotherapy (SLIT) tablet contains standardized house dust mite (HDM) allergen extract that is placed under the tongue, allowing direct mucosal immune exposure. The mechanism involves gradual desensitization of the immune system through induction of regulatory T cells and shift from Th2 to Th1/Treg responses, reducing IgE-mediated allergic inflammation and clinical symptoms.
Approved indications
- Allergic rhinitis and/or allergic asthma induced by house dust mite allergen
Common side effects
- Oral pruritus
- Throat irritation
- Mouth edema
- Local allergic reactions
Key clinical trials
- A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65 (PHASE3)
- Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy (PHASE2)
- Dupilumab and House Dust Mite Immunotherapy in Patients With Atopic Dermatitis (NA)
- House Dust Mite Allergy Trial In Children (PHASE3)
- Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
- Mite Asthma Pediatric Immunotherapy Trial (PHASE3)
- Adolescent Mite Allergy Safety Evaluation (PHASE3)
- A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HDM SLIT-tablet CI brief — competitive landscape report
- HDM SLIT-tablet updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI